Expanding a Brand: Statins and PPAR-Gamma Agonists to Treat Neurological Disease

Published by	Decision Resources, Inc.
Published	December, 2006	Product code	48001
Content info	17 Pages
Price	Not Available

Introduction
Related Reports

This publication has been discontinued on December 21, 2011.

Introduction

Abstract

Introduction:

The repositioning of agents to treat neurodegenerative disorders represents a signifi cant opportunity for companies that have products in highly competitive markets. Although the value of neurodegenerative markets is small by comparison, the signifi cant unmet need and the severity of these diseases mean that an emerging agent that can offer even a modest improvement over available therapies is likely to establish a share in the market.

Get the Answers You Need to Shape Your Strategy:

Both Alzheimer' s disease (AD) and multiple sclerosis (MS) have relatively small patient populations. Nevertheless, what factors make these two markets especially appealing to drug developers interested in repositioning their drugs? Similarities between the pathogenesis of AD and the pathogenesis of cardiovascular disease suggest that statins may have some effect on AD. What are the similarities, and what have been the results of clinical trials thus far?

Likewise, there are a number of connections between insulin metabolism and AD. Diabetes is, in fact, a risk factor for AD. What are the connections, and what have been the results of clinical trials investigating the effect of PPAR-gamma agonists on AD? Pfi zer and GlaxoSmithKline are two major drug developers actively seeking to reposition their products into the neurological markets (Pfi zer with its statin Lipitor [atorvastatin] and GlaxoSmithKline with its PPAR-gamma agonist Avandia [rosiglitazone]). What are the factors behind these companies' decisions to investigate new markets?

Scope:

The AD therapy market: key statistics.
The MS therapy market: key statistics.
Use of statins in treating AD: similarities in disease pathophysiology and clinical support for statin use.
Use of statins in treating MS: similarities in disease pathophysiology and clinical support for statin use.
Use of PPAR-gamma agonists in treating AD: similarities in disease pathophysiology and clinical support for statin use.

Mentioned in This Spectrum Report:

Companies/Institutes

Bayhill Therapeutics
Biogen Idec
Eisai
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck
National Institute on Aging
Pfi zer
Serono
Sun Research Institute
Takeda
Teva Pharmaceuticals

Drugs

Actos (pioglitazone)
Aricept (donepezil)
Avandia (rosiglitazone)
Avonex (interferon beta-1a)
BHT-3009
Copaxone (glatiramer acetate)
Lipitor (atorvastatin)
Rebif (interferon beta-1a)
Topamax (topiramate)
Zocor (simvastatin)

Executive Summary
Strategic Considerations
Stakeholder Implications
Introduction
Opportunity in Neurological Disease Markets
The Alzheimer' s Disease Market
The Multiple Sclerosis Market
The Use of Statins in Treating Alzheimer' s Disease
Pathophysiology of Alzheimer' s Disease
Statins' Potential Effect on Alzheimer' s Disease
Clinical Support for Statin Use in Treating Alzheimer' s Disease
Commercial Interest in Developing Statins for Alzheimer' s Disease
The Use of Statins in Treating Multiple Sclerosis
Pathophysiology of Multiple Sclerosis
Statins' Potential Effect on Multiple Sclerosis
Clinical Support for Statin Use in Multiple Sclerosis
Commercial Interest in the Development of Statins for Multiple Sclerosis
The Use of PPAR-Gamma Agonists in the Treatment of Alzheimer' s Disease
Potential Effect on Alzheimer' s Disease
Clinical Support for PPAR-Gamma Agonists in Alzheimer' s Disease
Commercial Interest in Developing PPAR-Gamma Agonists for Alzheimer' s Disease
Outlook

Tables

1. Leading Agents to Treat Alzheimer' s Disease in the Major Pharmaceutical Markets, 2005
2. Leading Agents to Treat Multiple Sclerosis in the Major Pharmaceutical Markets, 2005
3. Pfizer' s Lipitor: A Fact Sheet
4. Clinical Trials Investigating the Use of Statins to Treat Multiple Sclerosis
5. Pfizer' s Top-Selling Products, 2005